Amyloid beta (A?), the hallmark of Alzheimer's Disease (AD), now appears to be deleterious in its low number aggregate form as opposed to the macroscopic A? fibers historically seen postmortem. While Alzheimer targets, such as the tau protein, amyloid precursor protein (APP) processing, and immune system activation continue to be investigated, the recent discovery that amyloid beta aggregates at lipid rafts and likely forms neurotoxic pores has led to a new paradigm regarding why past therapeutics may have failed and how to design the next round of compounds for clinical trials. An atomic resolution understanding of A? aggregates, which appear to exist in multiple conformations, is most desirable for future therapeutic development. The investigative difficulties, structures of these small A? aggregates, and current therapeutics are summarized in this review.

Creator

• Medhane, Cumbay

• Arbor, Sage

• LaFontaine, Mike

Language

• English

关键词

• Amyloid beta-Protein Precursor

• Alzheimer Disease

• Amyloid beta-Peptides

• Membrane Microdomains

Date created

• 3/24/2016

Resource type

• Article

Source

• com_fp_36

• The Yale Journal of Biology and Medicine

Rights statement

• http://rightsstatements.org/vocab/InC/1.0/